685 Preliminary results of MT-401 in post-transplant MRD+ AML patients
685 Preliminary results of MT-401 in post-transplant MRD+ AML patients
About this item
Full title
Author / Creator
Koneru, Mythili , Vera, Juan , Arslan, Shukaib , Liu, Hongtao , Magalhaes-Silverma, Margarida , Bejanyan, Nelli , DiStasi, Antonio , Oran, Betul , Hsu, Jingmei , McCallum, Robin , Quintero, Silvia , Garrett, Gerald , Wang, Karrie , Smith, Eric , Hoang, Tsvetelina , Shahim, Tara , Crisostomo, Jeannette , Wilga-Savitski, Anna , Pickering, Jennifer , Angelo, Laura and Smith, Anastasiya
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundMeasurable residual disease (MRD) testing has become more prevalent in AML. MRD positivity is associated with increased relapse risk and shorter survival in AML, and currently, there no approved therapies for these patients. Zedenoleucel (also known as MT-401) is a non-genetically modified allogeneic multi-tumor associated antigen (mTAA)-...
Alternative Titles
Full title
685 Preliminary results of MT-401 in post-transplant MRD+ AML patients
Authors, Artists and Contributors
Author / Creator
Vera, Juan
Arslan, Shukaib
Liu, Hongtao
Magalhaes-Silverma, Margarida
Bejanyan, Nelli
DiStasi, Antonio
Oran, Betul
Hsu, Jingmei
McCallum, Robin
Quintero, Silvia
Garrett, Gerald
Wang, Karrie
Smith, Eric
Hoang, Tsvetelina
Shahim, Tara
Crisostomo, Jeannette
Wilga-Savitski, Anna
Pickering, Jennifer
Angelo, Laura
Smith, Anastasiya
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2840785820
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2840785820
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-SITC2022.0685
